

Erratum to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies

David W. Woolston,^{1*} Nathan D. Lee,^{2*} Mazyar Shadman,^{1,2*} Elena Latorre-Esteves,² Xin Ray Tee,² Jeanne Fredrickson,² Brendan F. Kohn,² Chaitra Ujjani,^{1,2} Ashley Eckel,² Brian Till,^{1,2} Min Fang,^{1,2} Jerald Radich,^{1,2} Ivana Bozic,^{1,2#} Rosa Ana Risques^{2#} and Cecilia C.S. Yeung^{1,2#}

¹Fred Hutchinson Cancer Center and ²University of Washington, Seattle, WA, USA

*DWW, NDL, and MS contributed equally as first authors.

#IB, RAR, and CCSY contributed equally as senior authors.

Correspondence: C.S. Yeung_Cecilia
cyeung@fredhutch.org

Received: January 25, 2024.

Accepted: January 25, 2024.

<https://doi.org/10.3324/haematol.2024.285151>

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license



On page 837 of the article by Woolston *et al.*,¹ in the sentence reproduced below, “ibrutinib” should be replaced with “acalabrutinib”:

Incorrect sentence:

“Sample R002-A was collected after 3 months of combination therapy with ibrutinib and venetoclax.”

Correct sentence:

“Sample R002-A was collected after 3 months of combination therapy with acalabrutinib and venetoclax.”

References

1. Woolston DW, Lee ND, Shadman M, et al. Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies. *Haematologica*. 2024;109(3):835-845.